
June 25 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O:
AMNEAL HIGHLIGHTS POSITIVE TOPLINE RESULTS FROM CONFIRMATORY CLINICAL STUDY OF BIOSIMILAR CANDIDATE TO XOLAIR(R) (OMALIZUMAB), DEVELOPED BY KASHIV BIOSCIENCES
AMNEAL PHARMACEUTICALS INC - ADL-018 CLINICAL STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS
AMNEAL PHARMACEUTICALS INC - BLA FOR ADL-018 EXPECTED TO BE SUBMITTED TO FDA IN Q4 2025